The earnings call highlights Vir Biotechnology's significant progress in their ECLIPSE program and T cell engager portfolio, alongside a strong financial position and reduced operating expenses. However, the company continues to face challenges with net losses and estimating the HDV patient population.

Company Guidance

During the call, Vir Biotechnology provided guidance on several key metrics. They reported significant advancements in their hepatitis delta (HDV) and oncology programs. The ECLIPSE registrational program for HDV is actively recruiting patients globally, with ECLIPSE 1 expected to complete primary endpoint data by December 2026. The company highlighted the commercial potential of their HDV treatment, given the estimated 7 million active viremic HDV RNA-positive patients worldwide, including 61,000 in the U.S. They anticipate a targeted commercial approach in major urban centers. In oncology, Vir has initiated a Phase I study for VIR-5525, their EGFR-targeted T cell engager, and continues to progress with VIR-5818 and VIR-5500 in Phase I studies. Financially, Vir ended the second quarter with $892 million in cash, providing a runway into mid-2027. R&D expenses were $97.5 million, a decrease from the previous year, attributed to restructuring initiatives, while SG&A expenses were $22.3 million. Net loss for the quarter was $111 million, down from $138.4 million in the same period of 2024.

Progress in the ECLIPSE Program

Vir Biotechnology has successfully enrolled the first patients in ECLIPSE 2 and ECLIPSE 3, with all three registrational studies actively recruiting patients globally. The primary completion for ECLIPSE 1 is expected by December 2026.

Advancements in T Cell Engager Programs

Vir has initiated a Phase I study for VIR-5525, their EGFR-targeted T cell engager, marking their third clinical stage T cell engager program. They also received IND clearance to evaluate VIR-5500 in earlier lines of prostate cancer treatment.

Strong Financial Position

Vir Biotechnology ended the second quarter with approximately $892 million in cash, cash equivalents, and investments, providing a cash runway extending into mid-2027.

Decreased Operating Expenses

Operating expenses in Q2 2025 were $119.6 million, a $42.1 million decrease from the same period in 2024, due to cost savings from restructuring initiatives and reduced stock-based compensation.

ECLIPSE Program Market Potential

The ECLIPSE program targets approximately 7 million active viremic HDV RNA-positive patients globally, with a significant concentration in major urban centers in the U.S., offering a compelling commercial opportunity.

Vir Biotechnology (VIR) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

VIR Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 30, 2025	2025 (Q3)	-0.84 / -	-1.56	―	―	―
Aug 06, 2025	2025 (Q2)	-0.72 / -0.80	-1.02	21.57% (+0.22)
May 07, 2025	2025 (Q1)	-0.84 / -0.88	-0.48	-83.33% (-0.40)	―
Feb 26, 2025	2024 (Q4)	-0.87 / -0.76	-0.86	11.63% (+0.10)
Oct 31, 2024	2024 (Q3)	-1.05 / -1.56	-1.22	-27.87% (-0.34)
Aug 01, 2024	2024 (Q2)	-0.90 / -1.02	-1.45	29.66% (+0.43)
May 02, 2024	2024 (Q1)	-1.05 / -0.48	-1.06	54.72% (+0.58)
Feb 22, 2024	2023 (Q4)	-1.01 / -0.86	-0.76	-13.16% (-0.10)
Nov 02, 2023	2023 (Q3)	-1.21 / -1.22	1.3	-193.85% (-2.52)
Aug 03, 2023	2023 (Q2)	-1.20 / -1.45	-0.58	-150.00% (-0.87)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

VIR Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 06, 2025	$5.08	$4.35	-14.37%
May 07, 2025	$5.61	$5.41	-3.57%
Feb 26, 2025	$9.20	$8.11	-11.85%
Oct 31, 2024	$7.49	$9.26	+23.63%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Vir Biotechnology (VIR) report earnings?

Vir Biotechnology (VIR) is schdueled to report earning on Oct 30, 2025, After Close (Confirmed).

What is Vir Biotechnology (VIR) earnings time?

Vir Biotechnology (VIR) earnings time is at Oct 30, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is VIR EPS forecast?

VIR EPS forecast for the fiscal quarter 2025 (Q3) is -0.84.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing